{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T12:00:12Z","timestamp":1780920012117,"version":"3.54.1"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s40261-025-01424-z","type":"journal-article","created":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T14:35:15Z","timestamp":1740494115000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Cost Effectiveness of Adjunctive Medical Cannabis Therapy in the Treatment of Moderate Post-Traumatic Stress Disorder"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5558-2218","authenticated-orcid":false,"given":"Mitchell L.","family":"Doucette","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipak","family":"Hemraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Luke","family":"Macfarlan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junella","family":"Chin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily","family":"Fisher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,25]]},"reference":[{"key":"1424_CR1","unstructured":"How Common is PTSD in Adults? PTSD: National Center for PTSD [Internet]. [cited 2024 Feb 14]. Available from: https:\/\/www.ptsd.va.gov\/understand\/common\/common_adults.asp. Accessed 14 Feb 2024."},{"key":"1424_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/wps.20656","volume":"18","author":"RA Bryant","year":"2019","unstructured":"Bryant RA. Post-traumatic stress disorder: a state-of-the-art review of evidence and challenges. World Psychiatry. 2019;18:259\u201369.","journal-title":"World Psychiatry"},{"key":"1424_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11920-020-1140-y","volume":"22","author":"DM Christiansen","year":"2020","unstructured":"Christiansen DM, Berke ET. Gender- and sex-based contributors to sex differences in PTSD. Curr Psychiatry Rep. 2020;22:19.","journal-title":"Curr Psychiatry Rep"},{"key":"1424_CR4","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1177\/070674371405900902","volume":"59","author":"J Sareen","year":"2014","unstructured":"Sareen J. Posttraumatic stress disorder in adults: impact, comorbidity, risk factors, and treatment. Can J Psychiatry. 2014;59:460\u20137.","journal-title":"Can J Psychiatry"},{"key":"1424_CR5","doi-asserted-by":"publisher","first-page":"2388","DOI":"10.1001\/jama.2018.7028","volume":"319","author":"H Song","year":"2018","unstructured":"Song H, Fang F, Tomasson G, Arnberg FK, Mataix-Cols D, Fern\u00e1ndez De La Cruz L, et al. Association of stress-related disorders with subsequent autoimmune disease. JAMA. 2018;319:2388.","journal-title":"JAMA"},{"key":"1424_CR6","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.ahj.2013.07.031","volume":"166","author":"D Edmondson","year":"2013","unstructured":"Edmondson D, Kronish IM, Shaffer JA, Falzon L, Burg MM. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J. 2013;166:806\u201314.","journal-title":"Am Heart J"},{"key":"1424_CR7","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/medicina55090525","volume":"55","author":"L Orsolini","year":"2019","unstructured":"Orsolini L, Chiappini S, Volpe U, De Berardis D, Latini R, Papanti GD, et al. Use of medicinal cannabis and synthetic cannabinoids in post-traumatic stress disorder (PTSD): a systematic review. Medicina (Kaunas). 2019;55:525.","journal-title":"Medicina (Kaunas)"},{"key":"1424_CR8","first-page":"546","volume":"118","author":"C Schrader","year":"2021","unstructured":"Schrader C, Ross A. A review of PTSD and current treatment strategies. Mo Med. 2021;118:546\u201351.","journal-title":"Mo Med"},{"key":"1424_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1097\/PRA.0000000000000091","volume":"21","author":"J Guina","year":"2015","unstructured":"Guina J, Rossetter SR, DeRHODES BJ, Nahhas RW, Welton RS. Benzodiazepines for PTSD: a systematic review and meta-analysis. J Psychiatr Pract. 2015;21:281\u2013303.","journal-title":"J Psychiatr Pract"},{"key":"1424_CR10","first-page":"32","volume":"37","author":"W Alexander","year":"2012","unstructured":"Alexander W. Pharmacotherapy for post-traumatic stress disorder in combat veterans. P T. 2012;37:32\u20138.","journal-title":"P T"},{"key":"1424_CR11","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1038\/jes.2017.15","volume":"27","author":"H Huang","year":"2017","unstructured":"Huang H, Tornero-Velez R, Barzyk TM. Associations between socio-demographic characteristics and chemical concentrations contributing to cumulative exposures in the United States. J Expo Sci Environ Epidemiol. 2017;27:544\u201350.","journal-title":"J Expo Sci Environ Epidemiol"},{"key":"1424_CR12","doi-asserted-by":"publisher","first-page":"1802920","DOI":"10.1080\/20008198.2020.1802920","volume":"12","author":"MD Hoskins","year":"2021","unstructured":"Hoskins MD, Bridges J, Sinnerton R, Nakamura A, Underwood JFG, Slater A, et al. Pharmacological therapy for post-traumatic stress disorder: a systematic review and meta-analysis of monotherapy, augmentation and head-to-head approaches. Eur J Psychotraumatol. 2021;12:1802920.","journal-title":"Eur J Psychotraumatol"},{"key":"1424_CR13","doi-asserted-by":"publisher","first-page":"414","DOI":"10.3934\/Neuroscience.2021022","volume":"8","author":"Y Rehman","year":"2021","unstructured":"Rehman Y, Saini A, Huang S, Sood E, Gill R, Yanikomeroglu S. Cannabis in the management of PTSD: a systematic review. AIMS Neurosci. 2021;8:414\u201334.","journal-title":"AIMS Neurosci."},{"key":"1424_CR14","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1007\/s11920-015-0600-2","volume":"17","author":"GH Wynn","year":"2015","unstructured":"Wynn GH. Complementary and alternative medicine approaches in the treatment of PTSD. Curr Psychiatry Rep. 2015;17:600.","journal-title":"Curr Psychiatry Rep"},{"key":"1424_CR15","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1503\/jpn.170021","volume":"43","author":"JE Boyd","year":"2018","unstructured":"Boyd JE, Lanius RA, McKinnon MC. Mindfulness-based treatments for posttraumatic stress disorder: a review of the treatment literature and neurobiological evidence. J Psychiatry Neurosci. 2018;43:7\u201325.","journal-title":"J Psychiatry Neurosci"},{"key":"1424_CR16","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/683293","volume":"2014","author":"T Numata","year":"2014","unstructured":"Numata T, Gunfan S, Takayama S, Takahashi S, Monma Y, Kaneko S, et al. Treatment of posttraumatic stress disorder using the traditional Japanese herbal medicine saikokeishikankyoto: a randomized, observer-blinded, controlled trial in survivors of the great East Japan earthquake and tsunami. Evid Based Complement Alternat Med. 2014;2014: 683293.","journal-title":"Evid Based Complement Alternat Med."},{"key":"1424_CR17","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s12906-020-03157-2","volume":"20","author":"M Tangkiatkumjai","year":"2020","unstructured":"Tangkiatkumjai M, Boardman H, Walker D-M. Potential factors that influence usage of complementary and alternative medicine worldwide: a systematic review. BMC Complement Med Ther. 2020;20:363.","journal-title":"BMC Complement Med Ther."},{"key":"1424_CR18","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1377\/hlthaff.2018.05266","volume":"38","author":"KF Boehnke","year":"2019","unstructured":"Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL. Qualifying conditions of medical cannabis license holders in the United States. Health Aff (Millwood). 2019;38:295\u2013302.","journal-title":"Health Aff (Millwood)."},{"key":"1424_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.2174\/187152709789824624","volume":"8","author":"MN Hill","year":"2009","unstructured":"Hill MN, Gorzalka BB. The endocannabinoid system and the treatment of mood and anxiety disorders. CNS Neurol Disord Drug Targets. 2009;8:451\u20138.","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"1424_CR20","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1016\/S0079-6123(10)82005-9","volume":"182","author":"P Pervanidou","year":"2010","unstructured":"Pervanidou P, Chrousos GP. Neuroendocrinology of post-traumatic stress disorder. Prog Brain Res. 2010;182:149\u201360.","journal-title":"Prog Brain Res"},{"key":"1424_CR21","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/j.1749-6632.2009.04979.x","volume":"1179","author":"R Yehuda","year":"2009","unstructured":"Yehuda R. Status of glucocorticoid alterations in post-traumatic stress disorder. Ann N Y Acad Sci. 2009;1179:56\u201369.","journal-title":"Ann N Y Acad Sci"},{"key":"1424_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1155\/2011\/328054","volume":"30","author":"C Sarapas","year":"2011","unstructured":"Sarapas C, Cai G, Bierer LM, Golier JA, Galea S, Ising M, et al. Genetic markers for PTSD risk and resilience among survivors of the World Trade Center attacks. Dis Markers. 2011;30:101\u201310.","journal-title":"Dis Markers"},{"key":"1424_CR23","doi-asserted-by":"publisher","first-page":"4850","DOI":"10.1523\/JNEUROSCI.23-12-04850.2003","volume":"23","author":"S Di","year":"2003","unstructured":"Di S, Malcher-Lopes R, Halmos KC, Tasker JG. Nongenomic glucocorticoid inhibition via endocannabinoid release in the hypothalamus: a fast feedback mechanism. J Neurosci. 2003;23:4850\u20137.","journal-title":"J Neurosci"},{"key":"1424_CR24","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/j.psyneuen.2010.03.005","volume":"35","author":"MN Hill","year":"2010","unstructured":"Hill MN, Karatsoreos IN, Hillard CJ, McEwen BS. Rapid elevations in limbic endocannabinoid content by glucocorticoid hormones in vivo. Psychoneuroendocrinology. 2010;35:1333\u20138.","journal-title":"Psychoneuroendocrinology"},{"key":"1424_CR25","doi-asserted-by":"publisher","first-page":"4811","DOI":"10.1210\/en.2010-0285","volume":"151","author":"NK Evanson","year":"2010","unstructured":"Evanson NK, Tasker JG, Hill MN, Hillard CJ, Herman JP. Fast feedback inhibition of the HPA axis by glucocorticoids is mediated by endocannabinoid signaling. Endocrinology. 2010;151:4811\u20139.","journal-title":"Endocrinology"},{"key":"1424_CR26","doi-asserted-by":"publisher","first-page":"10506","DOI":"10.1523\/JNEUROSCI.0496-11.2011","volume":"31","author":"MN Hill","year":"2011","unstructured":"Hill MN, McLaughlin RJ, Pan B, Fitzgerald ML, Roberts CJ, Lee TT-Y, et al. Recruitment of prefrontal cortical endocannabinoid signaling by glucocorticoids contributes to termination of the stress response. J Neurosci. 2011;31:10506\u201315.","journal-title":"J Neurosci"},{"key":"1424_CR27","doi-asserted-by":"publisher","first-page":"2952","DOI":"10.1016\/j.psyneuen.2013.08.004","volume":"38","author":"MN Hill","year":"2013","unstructured":"Hill MN, Bierer LM, Makotkine I, Golier JA, Galea S, McEwen BS, et al. Reductions in circulating endocannabinoid levels in individuals with post-traumatic stress disorder following exposure to the World Trade Center attacks. Psychoneuroendocrinology. 2013;38:2952\u201361.","journal-title":"Psychoneuroendocrinology"},{"key":"1424_CR28","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1080\/14737175.2022.2155139","volume":"22","author":"M Pillai","year":"2022","unstructured":"Pillai M, Erridge S, Bapir L, Nicholas M, Dalavaye N, Holvey C, et al. Assessment of clinical outcomes in patients with post-traumatic stress disorder: analysis from the UK Medical Cannabis Registry. Expert Rev Neurother. 2022;22:1009\u201318.","journal-title":"Expert Rev Neurother"},{"key":"1424_CR29","doi-asserted-by":"publisher","DOI":"10.1192\/bjo.2024.13","volume":"10","author":"MT Lynskey","year":"2024","unstructured":"Lynskey MT, Athanasiou-Fragkouli A, Thurgur H, Schlag AK, Nutt DJ. Medicinal cannabis for treating post-traumatic stress disorder and comorbid depression: real-world evidence. BJPsych open. 2024;10: e62.","journal-title":"BJPsych open."},{"key":"1424_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.626853","volume":"9","author":"SP Cahill","year":"2021","unstructured":"Cahill SP, Lunn SE, Diaz P, Page JE. Evaluation of patient reported safety and efficacy of cannabis from a survey of medical cannabis patients in Canada. Front Public Health. 2021;9: 626853.","journal-title":"Front Public Health"},{"key":"1424_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.janxdis.2022.102632","volume":"92","author":"SR Sznitman","year":"2022","unstructured":"Sznitman SR, Meiri D, Amit BH, Rosenberg D, Greene T. Posttraumatic stress disorder, sleep and medical cannabis treatment: a daily diary study. J Anxiety Disord. 2022;92: 102632.","journal-title":"J Anxiety Disord"},{"key":"1424_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2022.1014630","author":"N Nacasch","year":"2023","unstructured":"Nacasch N, Avni C, Toren P. Medical cannabis for treatment-resistant combat PTSD. Fron Psychiatry [Internet]. 2023. https:\/\/doi.org\/10.3389\/fpsyt.2022.1014630.","journal-title":"Fron Psychiatry [Internet]"},{"key":"1424_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1007\/s40261-014-0212-3","volume":"34","author":"P Roitman","year":"2014","unstructured":"Roitman P, Mechoulam R, Cooper-Kazaz R, Shalev A. Preliminary, open-label, pilot study of add-on oral \u03949-tetrahydrocannabinol in chronic post-traumatic stress disorder. Clin Drug Investig. 2014;34:587\u201391.","journal-title":"Clin Drug Investig"},{"key":"1424_CR34","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.euroneuro.2020.04.009","volume":"36","author":"E Krediet","year":"2020","unstructured":"Krediet E, Janssen DG, Heerdink ER, Egberts TC, Vermetten E. Experiences with medical cannabis in the treatment of veterans with PTSD: results from a focus group discussion. Eur Neuropsychopharmacol. 2020;36:244\u201354.","journal-title":"Eur Neuropsychopharmacol"},{"key":"1424_CR35","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1016\/j.jad.2020.05.132","volume":"274","author":"EM LaFrance","year":"2020","unstructured":"LaFrance EM, Glodosky NC, Bonn-Miller M, Cuttler C. Short and long-term effects of cannabis on symptoms of post-traumatic stress disorder. J Affect Disord. 2020;274:298\u2013304.","journal-title":"J Affect Disord"},{"key":"1424_CR36","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S, Kohlmann T, Busschbach J, Golicki D, et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health. 2012;15:708\u201315.","journal-title":"Value Health."},{"key":"1424_CR37","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s11126-020-09814-6","volume":"92","author":"J Dams","year":"2021","unstructured":"Dams J, Rimane E, Steil R, Renneberg B, Rosner R, K\u00f6nig H-H. Reliability, validity and responsiveness of the EQ-5D-5L in assessing and valuing health status in adolescents and young adults with posttraumatic stress disorder: a randomized controlled trail. Psychiatr Q. 2021;92:459\u201371.","journal-title":"Psychiatr Q"},{"key":"1424_CR38","volume-title":"Applied methods of cost-effectiveness analysis in health care","author":"AM Gray","year":"2011","unstructured":"Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S. Applied methods of cost-effectiveness analysis in health care. Oxford: Oxford University Press; 2011."},{"key":"1424_CR39","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, Neumann PJ, Basu A, Brock DW, Feeny D, Krahn M, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u2013103.","journal-title":"JAMA"},{"key":"1424_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0167-6296(86)90020-2","volume":"5","author":"GW Torrance","year":"1986","unstructured":"Torrance GW. Measurement of health state utilities for economic appraisal. J Health Econ. 1986;5:1\u201330.","journal-title":"J Health Econ"},{"key":"1424_CR41","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1097\/MLR.0b013e31815c31a7","volume":"46","author":"RS Braithwaite","year":"2008","unstructured":"Braithwaite RS, Meltzer DO, King JT, Leslie D, Roberts MS. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349\u201356.","journal-title":"Med Care"},{"key":"1424_CR42","first-page":"415","volume":"10","author":"L Drost","year":"2017","unstructured":"Drost L, DeAngelis C, Lam H, Zaki P, Malek L, Chow E, et al. Efficacy of different varieties of medical cannabis in relieving symptoms in post-traumatic stress disorder (PTSD) patients. J Pain Manag. 2017;10:415\u201322.","journal-title":"J Pain Manag"},{"key":"1424_CR43","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s42238-021-00073-1","volume":"3","author":"A Bhaskar","year":"2021","unstructured":"Bhaskar A, Bell A, Boivin M, Briques W, Brown M, Clarke H, et al. Consensus recommendations on dosing and administration of medical cannabis to treat chronic pain: results of a modified Delphi process. J Cannabis Res. 2021;3:22.","journal-title":"J Cannabis Res."},{"key":"1424_CR44","doi-asserted-by":"publisher","first-page":"7471","DOI":"10.1007\/s00520-021-06301-x","volume":"29","author":"DM Zylla","year":"2021","unstructured":"Zylla DM, Eklund J, Gilmore G, Gavenda A, Guggisberg J, VazquezBenitez G, et al. A randomized trial of medical cannabis in patients with stage IV cancers to assess feasibility, dose requirements, impact on pain and opioid use, safety, and overall patient satisfaction. Support Care Cancer. 2021;29:7471\u20138.","journal-title":"Support Care Cancer"},{"key":"1424_CR45","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1016\/j.jval.2021.04.1276","volume":"24","author":"D Erku","year":"2021","unstructured":"Erku D, Shrestha S, Scuffham P. Cost-effectiveness of medicinal cannabis for management of refractory symptoms associated with chronic conditions: a systematic review of economic evaluations. Value in Health. 2021;24:1520\u201330.","journal-title":"Value in Health."},{"key":"1424_CR46","first-page":"117954412110024","volume":"14","author":"C Vannabouathong","year":"2021","unstructured":"Vannabouathong C, Zhu M, Chang Y, Bhandari M. Can medical cannabis therapies be cost-effective in the non-surgical management of chronic knee pain? Clin. 2021;14:11795441211002492.","journal-title":"Clin"},{"key":"1424_CR47","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1089\/can.2018.0027","volume":"4","author":"GA Tyree","year":"2019","unstructured":"Tyree GA, Sarkar R, Bellows BK, Ellis RJ, Atkinson JH, Marcotte TD, et al. A Cost-Effectiveness Model for Adjunctive Smoked Cannabis in the Treatment of Chronic Neuropathic Pain. Cannabis and Cannabinoid Research. 2019;4:62\u201372.","journal-title":"Cannabis and Cannabinoid Research."},{"key":"1424_CR48","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1080\/14737167.2024.2412248","volume":"25","author":"S Marrinan","year":"2025","unstructured":"Marrinan S, Schlag AK, Lynskey M, Seaman C, Barnes MP, Morgan-Giles M, et al. An early economic analysis of medical cannabis for the treatment of chronic pain. Expert Rev Pharmacoecon Outcomes Res. 2025;25:39\u201352.","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"1424_CR49","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1080\/15265161.2019.1567193","volume":"19","author":"D Casarett","year":"2019","unstructured":"Casarett D, Abrams DI. Why Insurance Companies Should Pay for Medical Cannabis. Am J Bioeth. 2019;19:8\u201310.","journal-title":"Am J Bioeth"},{"key":"1424_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1159\/000505028","volume":"3","author":"AK Schlag","year":"2020","unstructured":"Schlag AK. An Evaluation of Regulatory Regimes of Medical Cannabis: What Lessons Can Be Learned for the UK? Medical Cannabis and Cannabinoids. 2020;3:76\u201383.","journal-title":"Medical Cannabis and Cannabinoids."},{"key":"1424_CR51","unstructured":"Sousa S. Connecticut workers\u2019 compensation coverage for medical cannabis in the age of the opioid crisis. Connecticut Law Rev. 2022;53:945."},{"key":"1424_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104143","volume":"119","author":"AC Cook","year":"2023","unstructured":"Cook AC, Sirmans ET, Stype A. Medical cannabis laws lower individual market health insurance premiums. Int J Drug Policy. 2023;119: 104143.","journal-title":"Int J Drug Policy"},{"key":"1424_CR53","doi-asserted-by":"publisher","DOI":"10.1007\/s40258-024-00913-0","author":"ML Doucette","year":"2024","unstructured":"Doucette ML, Hemraj D, Fisher E, Macfarlan DL. Measuring the impact of medical cannabis law adoption on employer-sponsored health insurance costs: a difference-in-difference analysis, 2003\u20132022. Appl Health Econ Health Policy [Internet]. 2024. https:\/\/doi.org\/10.1007\/s40258-024-00913-0.","journal-title":"Appl Health Econ Health Policy [Internet]"},{"key":"1424_CR54","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0239997","volume":"15","author":"E Marseille","year":"2020","unstructured":"Marseille E, Kahn JG, Yazar-Klosinski B, Doblin R. The cost-effectiveness of MDMA-assisted psychotherapy for the treatment of chronic, treatment-resistant PTSD. PLoS ONE. 2020;15: e0239997.","journal-title":"PLoS ONE"},{"key":"1424_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263252","volume":"17","author":"E Marseille","year":"2022","unstructured":"Marseille E, Mitchell JM, Kahn JG. Updated cost-effectiveness of MDMA-assisted therapy for the treatment of posttraumatic stress disorder in the United States: Findings from a phase 3 trial. PLoS ONE. 2022;17: e0263252.","journal-title":"PLoS ONE"},{"key":"1424_CR56","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s40261-022-01122-0","volume":"42","author":"ALV Avance\u00f1a","year":"2022","unstructured":"Avance\u00f1a ALV, Kahn JG, Marseille E. The costs and health benefits of expanded access to MDMA-assisted therapy for chronic and severe PTSD in the USA: a modeling study. Clin Drug Investig. 2022;42:243\u201352.","journal-title":"Clin Drug Investig"},{"key":"1424_CR57","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1089\/can.2020.0120","volume":"7","author":"M Kalaba","year":"2022","unstructured":"Kalaba M, Ware MA. Cannabinoid profiles in medical cannabis users: effects of age, gender, symptoms, and duration of use. Cannabis Cannabinoid Res. 2022;7:840\u201351.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1424_CR58","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/s12913-016-1805-8","volume":"16","author":"W Tao","year":"2016","unstructured":"Tao W, Agerholm J, Burstr\u00f6m B. The impact of reimbursement systems on equity in access and quality of primary care: a systematic literature review. BMC Health Serv Res. 2016;16:542.","journal-title":"BMC Health Serv Res"},{"key":"1424_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.116717","volume":"411","author":"EA Levinsohn","year":"2020","unstructured":"Levinsohn EA, Hill KP. Clinical uses of cannabis and cannabinoids in the United States. J Neurol Sci. 2020;411: 116717.","journal-title":"J Neurol Sci"},{"key":"1424_CR60","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.ejim.2018.01.004","volume":"49","author":"CA MacCallum","year":"2018","unstructured":"MacCallum CA, Russo EB. Practical considerations in medical cannabis administration and dosing. Eur J Intern Med. 2018;49:12\u20139.","journal-title":"Eur J Intern Med"},{"key":"1424_CR61","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s41030-021-00171-8","volume":"7","author":"AG Kaplan","year":"2021","unstructured":"Kaplan AG. Cannabis and lung health: does the bad outweigh the good? Pulm Ther. 2021;7:395\u2013408.","journal-title":"Pulm Ther."},{"key":"1424_CR62","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030178","volume":"13","author":"AM Jeffers","year":"2024","unstructured":"Jeffers AM, Glantz S, Byers AL, Keyhani S. Association of cannabis use with cardiovascular outcomes among US adults. J Am Heart Assoc. 2024;13: e030178.","journal-title":"J Am Heart Assoc"},{"key":"1424_CR63","doi-asserted-by":"crossref","unstructured":"Purcell C, Davis A, Moolman N, Taylor SM. Reduction of Benzodiazepine Use in Patients Prescribed Medical Cannabis. Cannabis Cannabinoid Res. 2019;4(3):214\u20138.","DOI":"10.1089\/can.2018.0020"},{"key":"1424_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhealeco.2019.102273","volume":"69","author":"BJ McMichael","year":"2020","unstructured":"McMichael BJ, Van Horn RL, Viscusi WK. The impact of cannabis access laws on opioid prescribing. J Health Econ. 2020;69: 102273.","journal-title":"J Health Econ"},{"key":"1424_CR65","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.54573","volume":"6","author":"T Nguyen","year":"2023","unstructured":"Nguyen T, Li Y, Greene D, Stancliff S, Quackenbush N. Changes in prescribed opioid dosages among patients receiving medical cannabis for chronic pain, New York State, 2017\u20132019. JAMA Netw Open. 2023;6: e2254573.","journal-title":"JAMA Netw Open"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01424-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01424-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01424-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:38:42Z","timestamp":1744004322000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01424-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,25]]},"references-count":65,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1424"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01424-z","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,25]]},"assertion":[{"value":"29 January 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors MLD, DH, EF, JC, and DLM are employees of Leafwell and hold stock or stock options in Leafwell. Leafwell is a Telehealth company that connects potential medical cannabis patients to physicians in a friendly PC model. Leafwell does not produce or sell cannabis products. No grant funding was used to sponsor this research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This research was not supported by any grants or external funding.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors have approved the final manuscript version.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All data on costs and utilities are from publicly available resources.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Please reach out to the corresponding author for microsimulation code.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed equally to the development and production of this manuscript. Author MLD lead data acquisition and analysis. All authors approved the final manuscript version.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}